Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and…
The anticancer drug iza-bren, developed by Sichuan Biokin Pharmaceutical, demonstrated a significant improvement in lung cancer survival rates in a phase 3 clinical trial conducted in China. Published online by The Lancet, the study involved 432 patients with advanced lung cancer and found that iza-bren doubled the median progression-free survival time compared to platinum-based chemotherapy.
While iza-bren showed a higher incidence of adverse reactions, mainly affecting blood cell counts, no new safety concerns were identified. iza-bren is a first-in-class bispecific antibody-drug conjugate that targets two tumor-associated antigens, EGFR and HER3, and is the world's first approved bispecific ADC. The drug has already been approved for two indications in China and has marketing applications under review for lung cancer and two types of breast cancer.
China has become a leading global hub for clinical trial registrations and early-stage drug development, with a growing number of patients seeking access to innovative therapies like iza-bren.
Written by urgent.news from Reuters Business via SCMP's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
